BPC-157 Legal Status in the US: What You Need to Know

The legal status of BPC-157 in the United States is straightforward in principle but layered in practice. It is not an approved drug, not a controlled substance, and not banned from sale. The complication is the FDA's 2024 Category 2 designation, which affects compounding but not research-use purchases. Here is the current picture with primary source links.

FDA Position on BPC-157

The FDA has not approved BPC-157 for any therapeutic use. No company has submitted a New Drug Application for it. The FDA's involvement centers on compounding regulation.

The 2024 Category 2 Designation

In 2024, the FDA placed BPC-157 on its Category 2 list of bulk drug substances nominated for compounding. Category 2 means the FDA has identified safety or quality concerns and is evaluating whether to permit or prohibit compounding. This designation does not make BPC-157 illegal. It signals that the FDA may impose restrictions on compounding pharmacies in the future.

What Category 2 Means for Compounding

Some compounding pharmacies stopped making BPC-157 after the Category 2 designation as a precautionary measure. Others continue to compound it while the review is ongoing. The FDA has not issued a final rule prohibiting compounding. Patients with active prescriptions should check with their pharmacy about continued availability.

WADA and Sport

The World Anti-Doping Agency treats BPC-157 differently than the FDA does.

Prohibited Status Under S0

BPC-157 is prohibited at all times under WADA's Prohibited List, specifically under category S0 (non-approved substances). S0 covers any pharmacological substance not addressed by other sections of the list that is not currently approved for human therapeutic use. Because BPC-157 has no FDA approval, it falls squarely under S0.

What Athletes Should Know

Any athlete subject to WADA testing (Olympic, collegiate NCAA, professional leagues that follow WADA rules) should not use BPC-157. A positive test or even possession could result in a suspension. This applies regardless of the source: research vendor, compounding pharmacy or clinic. The prohibition is absolute during competition and out of competition.

State-Level Considerations

Federal law sets the baseline. Some states add their own layers.

States with Additional Restrictions

As of October 2026, no US state has specifically banned the purchase or possession of BPC-157 for personal use. However, some states have enacted broader legislation affecting peptide sales or compounding pharmacy practices that could indirectly impact availability. State pharmacy boards control which substances a compounding pharmacy may prepare, and some boards have been more restrictive following the FDA's Category 2 review.

Telehealth Prescribing Rules by State

Telehealth prescribing of compounded peptides is subject to each state's telemedicine laws. Most states allow prescribing via telehealth, but a few require an initial in-person visit. The prescriber must hold an active license in the state where the patient is located. Our peptide clinic guide covers the telehealth route in detail.

Buying for Research Use

The research-use channel operates under a different legal framework than the pharmaceutical channel.

How Research-Use Labeling Works

Products labeled "for research use only" or "not for human consumption" are not marketed as drugs. The vendor makes no therapeutic claims. This removes the product from the FDA's drug approval requirements. The buyer takes responsibility for how the product is used. This is the legal basis under which most online peptide vendors operate.

What the Seller Must Include

A research chemical vendor should clearly label the product with its chemical name, quantity, lot number and a statement that it is for research use only. Beyond labeling, there is no federal licensing requirement specific to selling research peptides, though general business and commerce regulations still apply.

Sources and Verification Date